Bioventus revises and backloads the CartiHeal acquisition deal

By

This is a sign of the financial situation in late 2022 where acquirers have a lower tolerance for risk.
Original deal was $315M up front + $100M if future milestones are met.
Revised deal is $100M up front + $215M if future milestones are met.

Is BioVentus taking advantage of the new financial macro landscape to put less capitial up front?
Or is BioVentus having to finance the deal with higher debt rates?

Read my alert in May - WARNING: The tightening is beginning.

NEW PRESS RELEASE
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for act...

Your friends are reading OrthoStreams daily - Are you ?

 

Unlock your access to full rich article, trends, hot startups, market reports and your daily newsletter.

Just $1/day.